ASCO 2020：11项东亚研究入选口头报告，17项Poster报告

受全球上新冠疫情严重影响，原定于5年底29日~6年底2日在芝加哥闭幕的新泽西州流行病学该协会（ASCO）大会今年将首次以线或上型式承办，这是在此之前最大规模的线或上盛会。今日，代表大会的简述题目公布，共103个sessions，中的国共有11项研究工作入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨常用HER2+乳腺癌乳腺膀胱癌（PHOEBE）：一项III期随机试验车。

交响乐：乳腺癌乳腺膀胱癌

著者：中的国医学科学院的医院徐兵河大学教授、马飞大学教授，复旦大学附属的医院胡夕春大学教授等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三阴适度乳腺膀胱癌规格外科开刀后卡培他滨维持节拍疗程的III期试验车（SYSUCC-001）。

交响乐：乳腺膀胱癌—发散/区域/除此以外外科开刀

著者：中的山大学传染病中的心王时树森大学教授等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

借助乳腺癌脑的表型特征来预测消化道中的循环系统DNA测定的概率: 上新工具对抗据说对手

交响乐：上新工具解决据说弊端

著者：李美芹 李德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对瓦努阿图拉非尼作为中叶消化道内膀胱癌的队内外科开刀：一项封闭ID、随机、多中的心II/III期试验车。

交响乐：腹腔肠道膀胱癌—腹腔十二指肠、凋亡和肾脏胆

著者：重庆大学棱果的医院毕锋大学教授、中的国国民解放军朝阳的医院秦叔逵大学教授等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国中叶肾脏膀胱癌患儿阿帕替尼一线或外科开刀：一项随机、安慰剂对照、双盲III期研究工作

交响乐：腹腔肠道膀胱癌—腹腔十二指肠、凋亡和肾脏胆

著者：中的国国民解放军朝阳的医院秦叔逵大学教授、重庆大学棱果的医院李秋大学教授等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中叶患上适度卵巢膀胱癌二次蛋白减灭术的一项随机III期试验车：SOC1 / SGOG-OV2。

时事：针灸膀胱前列腺癌

著者：复旦大学附属中的山的医院臧荣余大学教授等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈膀胱癌根治适度子宫切除术后除此以外外科开刀中的的序贯放疗程对比单独疗程或同步放疗程（STARS研究工作）：一项随机、对照、封闭ID的III期试验车。

代表大会：针灸膀胱前列腺癌

著者：中的山大学传染病中的心凌云大学教授、刘继红大学教授等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比疗程常用可切除的EGFR凋亡的N1-N2期NSCLC-随机III期流行病学试验车的终于总体猎食深入研究工作。

时事：肺膀胱癌—非小蛋白发散-区域/小蛋白/其他胸部

著者：广东省国民的医院吴一龙大学教授等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡无以转回非小蛋白肺膀胱癌患儿队内色氨酸激酶类固醇牵头或不牵头更进一步主力部队或发散疗程：III期封闭ID流行病学随机试验车（SINDAS）的中的期结果（NCT02893332）。

时事：肺膀胱癌-非小蛋白转回

著者：四川省国民的医院曾铭大学教授等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序适度失踪-1（PD-1）的人源化IgG4单克隆抗体牵头阿昔替尼常用乳腺癌口腔黑色素肿患儿的Ib期研究工作的总猎食期和脊椎动物标志物深入研究工作。

时事：黑色素肿/皮肤膀胱癌

著者：北京大学的医院郭军、盛锡楠大学教授等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全适度和结果：国际标准化组织CAR-T蛋白首次消化道试验车外科开刀患上/难治适度T蛋白急适度淋巴蛋白乳癌（r/r T-ALL）的安全适度和。代表大会：合作开发中的的外科开刀技术-免疫外科开刀。著者：王时林欣等简述：3013年底历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中叶十二指肠鳞状蛋白膀胱癌患儿中的的应用：一项随机的封闭IDII期试验车（ORIENT-2）。代表大会：腹腔肠道膀胱癌-腹腔十二指肠膀胱癌、凋亡膀胱癌和肾脏胆道膀胱癌著者：徐建明大学教授等简述：4511年底历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异适度CAR-T蛋白对质母蛋白肿的根除适度外科开刀代表大会：中的枢神经系统著者：代红久、孙斌、杨东、徐晖、潘晶晶、魏佳、赵旭东简述：2522年底历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中叶错配修复缺陷患儿中的的应用代表大会：合作开发中的的外科开刀学-免疫外科开刀著者：沈琳大学教授等简述：3021年底历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 免疫CD7-CART外科开刀患上/难治适度ACUTE淋巴蛋白乳癌/淋巴肿的元月消化道流行病学试验车代表大会: 合作开发适度外科开刀学-免疫外科开刀著者简介：张明志，杨林等简述：3026年底历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应常用中叶实质肿患儿的Ib期研究工作代表大会：发展适度外科开刀学--分子靶向药物和脊椎动物学著者：龚继芳，沈琳大学教授等简述：3523年底历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头紫杉醇和nedaplatin外科开刀患上适度或乳腺癌十二指肠鳞状蛋白膀胱癌（ESCC）患儿的II期研究工作。代表大会：腹腔肠道膀胱癌-腹腔十二指肠、凋亡和肾脏胆道膀胱癌的研究工作著者：王时志超强，李玉红，王时德申，王时凤华，任超，谭琼 王时志超强、李玉红、王时德深、王时凤华、任超、谭琼简述：4522年底历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大会：腹腔肠道膀胱癌-腹腔十二指肠膀胱癌、凋亡膀胱癌和肾脏胆管膀胱癌的一线或外科开刀著者：宋艳等简述：4524年底历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种排泄物外体环状RNA分类器常用初始活检时测定高等级膀胱癌的排泄物外体环状RNA分类器：一项多中的心的回顾适度研究工作代表大会：泌尿循环系统系统膀胱前列腺癌---膀胱癌、睾丸膀胱癌和膀胱癌著者简介：Liaoyuan Li等简述：5522年底历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散中叶宫颈膀胱癌并发疗程后的除此以外疗程代表大会: 针灸膀胱前列腺癌著者简介： 李珉珉等简述：6031年底历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼外科开刀肾脏脏质适度膀胱癌的相关适度：基于ALTER01031试验车的深入研究工作。会话：细弱著者：哈尔滨市的医院高深大学教授简述：6526年底历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小不一和年龄对安洛替尼外科开刀后患儿结尾的严重影响: ALTER01031的亚组深入研究工作代表大会：细弱著者：哈尔滨市的医院高深大学教授简述：6527年底历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究工作预测I-IIIA期非小蛋白肺膀胱癌（NSCLC）患儿术后患上: GASTO1035和GASTO1018的结果代表大会：肺膀胱癌-非小蛋白发散-区域适度/小蛋白/小蛋白/其他胸科膀胱前列腺癌著者：Si-Yu Wang等简述：9023年底历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白肺膀胱癌（NSCLC）中的EGFR色氨酸激酶类固醇的上新型MRSA系统代表大会:肺膀胱癌-非小蛋白乳腺癌肺膀胱癌著者简介：赵昕，金玲玲，满宇，欧名妓，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧名妓、华宝、薛武、杨绍、范敏简述：9528年底历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验车中的中叶黑色素肿总猎食的替代终点站代表大会：黑色素肿/皮肤膀胱癌著者：聂润聪，袁书超强，李元芳，陈英波，周志伟 聂润聪、袁书超强、李元芳、陈英波、周志伟简述：10030年底历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼外科开刀患上或乳腺癌原发适度恶适度骨患儿的II期研究工作代表大会： 遗传性著者：唐丽娜，牛晓辉，姚依林，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525年底历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在中叶遗传性患儿多线或外科开刀中的的安全适度和。代表大会：遗传性著者：姚伟涛，王时家超强，王时永，王时林，杜上新辉，田志浩，牛晓颖 姚伟涛、王时家超强、王时永、王时鑫、杜鑫辉、田志超、牛晓英简述：11526年底历：414